Literature DB >> 16148583

Macular symmetry testing for glaucoma detection.

Harmohina Bagga1, David S Greenfield, Robert W Knighton.   

Abstract

PURPOSE: To evaluate structural asymmetry in the macula using optical coherence tomography (OCT) in glaucomatous eyes with visual field defects localized to one hemifield.
METHODS: Complete examination, standard automated perimetry (SAP), and OCT imaging (512 A-scans) of the peripapillary retina and macula were performed. Exclusion criteria were visual acuity <20/40, diseases other than glaucoma, and SAP defects localized to both hemifields. Macular OCT images were obtained using four 5-mm radial scans centered on the foveola and passing obliquely through the macula (15 degrees superotemporally and inferotemporally). Macular measurements temporal to the fovea (T) were sub-divided into nasal (T1) and temporal (T2) segments. Macular symmetry testing (MST) was performed in T, T1, and T2 segments by comparing the mean macular thickness of the perimetrically abnormal and perimetrically normal hemi-zones (macular thickness in perimetrically normal hemi-zone/macular thickness in perimetrically abnormal hemi-zone x 100), and superior and inferior hemi-zones in normal subjects (macular thickness in superior hemi-zone/macular thickness in inferior hemi-zone x 100). MST measurements were considered to be abnormal if they exceeded the 95% limits of normal variability.
RESULTS: Forty eyes of 40 patients (20 normal, 20 glaucoma) were enrolled (mean age 60 +/- 19 years, range 21-89). All eyes with glaucoma had associated hemifield defect (average MD = -7.23 +/- 4.8 dB, range -0.9 to -15.4). In glaucomatous eyes, mean retinal thickness in T, T1, and T2 within the perimetrically abnormal hemi-zone (222 +/- 14 microm, 224+/- 17 microm, 221 +/-13 microm, respectively) was significantly less (P = 0.002, 0.008, 0.001, respectively) than the corresponding segments in the perimetrically normal hemi-zone (235 +/- 17 microm, 237 +/- 18 microm, 233 +/- 17 microm, respectively). Normal eyes showed no difference (P = 0.17, 0.20, 0.35) in T, T1, and T2 measurements within the superior hemi-zone (254 +/- 11, 249 +/- 14, 258 +/- 14) and inferior hemi-zone (252 +/- 11, 250 +/- 13, 255 +/- 13), respectively. MST values in glaucomatous eyes were outside 95% limits of normal variability in 17/20 (85%) T segments, 16 /20 (80%) T1 segments, and 16/20 (80%) T2 segments.
CONCLUSION: Localized macular thickness changes exist in glaucomatous eyes with regional visual field loss. The MST may represent a novel strategy for glaucoma diagnosis.

Entities:  

Mesh:

Year:  2005        PMID: 16148583     DOI: 10.1097/01.ijg.0000176930.21853.04

Source DB:  PubMed          Journal:  J Glaucoma        ISSN: 1057-0829            Impact factor:   2.503


  27 in total

1.  Detection of macular and circumpapillary structural loss in normal hemifield areas of glaucomatous eyes with localized visual field defects using spectral-domain optical coherence tomography.

Authors:  Jung Hwa Na; Michael S Kook; Youngrok Lee; Sung Jin Yu; Jaewan Choi
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-12-15       Impact factor: 3.117

2.  Structural and functional assessment by hemispheric asymmetry testing of the macular region in preperimetric glaucoma.

Authors:  Chiaki Kawaguchi; Yusuke Nakatani; Shinji Ohkubo; Tomomi Higashide; Ichiro Kawaguchi; Kazuhisa Sugiyama
Journal:  Jpn J Ophthalmol       Date:  2013-12-10       Impact factor: 2.447

3.  Peripapillary and Macular Vessel Density in Patients with Glaucoma and Single-Hemifield Visual Field Defect.

Authors:  Adeleh Yarmohammadi; Linda M Zangwill; Alberto Diniz-Filho; Luke J Saunders; Min Hee Suh; Zhichao Wu; Patricia Isabel C Manalastas; Tadamichi Akagi; Felipe A Medeiros; Robert N Weinreb
Journal:  Ophthalmology       Date:  2017-02-10       Impact factor: 12.079

4.  The accuracy and clinical application of predictive models for primary open-angle glaucoma in ocular hypertensive individuals.

Authors: 
Journal:  Ophthalmology       Date:  2008-09-18       Impact factor: 12.079

5.  Vertical Macular Asymmetry Measures Derived From SD-OCT for Detection of Early Glaucoma.

Authors:  Farideh Sharifipour; Esteban Morales; Ji Woong Lee; JoAnn Giaconi; Abdelmonem A Afifi; Fei Yu; Joseph Caprioli; Kouros Nouri-Mahdavi
Journal:  Invest Ophthalmol Vis Sci       Date:  2017-08-01       Impact factor: 4.799

6.  Improving glaucoma detection using spatially correspondent clusters of damage and by combining standard automated perimetry and optical coherence tomography.

Authors:  Ali S Raza; Xian Zhang; Carlos G V De Moraes; Charles A Reisman; Jeffrey M Liebmann; Robert Ritch; Donald C Hood
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-01-29       Impact factor: 4.799

7.  Tracking longitudinal retinal changes in experimental ocular hypertension using the cSLO and spectral domain-OCT.

Authors:  Li Guo; Eduardo M Normando; Shereen Nizari; David Lara; M Francesca Cordeiro
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-08-04       Impact factor: 4.799

8.  Sensitivity and specificity for detecting early glaucoma in eyes with high myopia from normative database of macular ganglion cell complex thickness obtained from normal non-myopic or highly myopic Asian eyes.

Authors:  Hideo Nakanishi; Tadamichi Akagi; Masanori Hangai; Yugo Kimura; Kenji Suda; Kyoko Kawashima Kumagai; Satoshi Morooka; Hanako Ohashi Ikeda; Nagahisa Yoshimura
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-05-06       Impact factor: 3.117

9.  Retinal blood flow in glaucomatous eyes with single-hemifield damage.

Authors:  Mitra Sehi; Iman Goharian; Ranjith Konduru; Ou Tan; Sowmya Srinivas; Srinivas R Sadda; Brian A Francis; David Huang; David S Greenfield
Journal:  Ophthalmology       Date:  2013-11-28       Impact factor: 12.079

Review 10.  Macular imaging with optical coherence tomography in glaucoma.

Authors:  Vahid Mohammadzadeh; Nima Fatehi; Adeleh Yarmohammadi; Ji Woong Lee; Farideh Sharifipour; Ramin Daneshvar; Joseph Caprioli; Kouros Nouri-Mahdavi
Journal:  Surv Ophthalmol       Date:  2020-03-19       Impact factor: 6.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.